Growth Factor Receptor Fusions Predict Therapeutic Sensitivity

Clin Cancer Res. 2015 Jul 15;21(14):3105-7. doi: 10.1158/1078-0432.CCR-15-0458. Epub 2015 May 20.

Abstract

Dysregulated growth factor pathways promote tumor growth in many cancers, but receptor-targeting strategies frequently offer limited benefit despite activation by receptor overexpression or amplification. In contrast, tumors harboring growth factor receptor fusions display exquisite dependence on receptor activity, providing predictive markers for patient response to inform precise oncology treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Brain Neoplasms / genetics*
  • Female
  • Glioma / genetics*
  • Humans
  • Male
  • Oncogene Proteins, Fusion / genetics*
  • Pyrazoles / therapeutic use*
  • Quinoxalines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Oncogene Proteins, Fusion
  • Pyrazoles
  • Quinoxalines